Key result
Full anticoagulation during hemodialysis maintained significantly higher dialyzer fiber patency (94%) compared to a 25% dose (74%), while revealing high intrapatient variability in fiber blocking.
Why the study?
Reliable parameters to quantify dialyzer fiber blocking are lacking, and intrapatient variability using micro-computed tomography imaging had not been systematically examined.
Does a reduced anticoagulation dose (25% of standard) compared to full dose affect dialyzer fiber blocking and thrombin generation in chronic hemodialysis patients, and what is the intrapatient variability?
RCT (n=10)
Single-blind
Two-arm cross-over
No
Does a reduced anticoagulation dose (25% of standard) compared to full dose affect dialyzer fiber blocking and thrombin generation in chronic hemodialysis patients, and what is the intrapatient variability?
High intrapatient variability in dialyzer fiber blocking complicates cross-sectional assessments of clotting, and whole blood thrombin generation markers lack sufficient predictive accuracy for clinical use.
Reduced anticoagulation impairs dialyzer fiber patency; high intrapatient variability (ICC ~0.5) complicates cross-sectional clotting assessments.
To date, no reliable blood-based or instrumental parameters are available to quantify dialyzer fiber blocking during hemodialysis. The only accurate method remains micro-computed tomography (µCT) imaging of the hemodialyzer post-dialysis, a labor-intensive process currently limited to research settings. Although several cross-sectional studies have employed µCT to evaluate hemodialyzer performance and anticoagulation strategies, intrapatient variability of this method has not been systematically examined. This study addressed that gap by enrolling ten chronic hemodialysis patients, each undergoing two series of three identical dialysis sessions: one with full anticoagulation and one with only 25% of the standard anticoagulation dose. µCT imaging after each session revealed important intrapatient variability in fiber blocking, comparable in magnitude to interpatient variability. These findings underscore the need for caution when interpreting cross-sectional assessments of dialyzer clotting and highlight the importance of accounting for intrapatient variability in the design and sample size estimation of future studies on clotting. Additionally, among the parameters derived from whole blood thrombin generation (WBTG) tests, only lag time and time to peak demonstrated correlations with fiber patency. However, due to their limited predictive accuracy at the individual level, even these promising markers fall short of providing clinically useful predictors for dialyzer fiber blocking.
No takes yet. Share an insight, caveat, or question.
Eloot et al. (2026) conducted an RCT in End-stage renal disease on maintenance hemodialysis (n=10). Low Molecular Weight Heparin (enoxaparin) vs. 25% of regular dose was evaluated on Dialyzer fiber patency measured by µCT scanning (p=<0.001). Full anticoagulation during hemodialysis maintained significantly higher dialyzer fiber patency (94%) compared to a 25% dose (74%), while revealing high intrapatient variability in fiber blocking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: